Purpose The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed.
Mild Clostridium difficile infection (CDI; stool frequency <four-times daily; no signs of severe colitis), clearly induced by the use of antibiotics, may be treated by stopping the inducing ...
Antibiotic treatment alters the intestinal microbiota resulting in hard-to-treat Clostridium difficile infections C. difficile produces toxins that damage intestinal cells and cause inflammation, ...
Hosted on MSN1mon
10 'superbug' stories from 2024, from bacterial 'Kryptonite' to deep-sea antibioticsIn the meantime, the superbugs also have a chance to share their antibiotic-resistant genes with other bacteria. The superbug Clostridioides difficile (formerly called Clostridium difficile ...
The benefits of antibiotics are well known, but the risks are not. In this video, Christian Lillis, son of Peggy Lillis, shares his personal story of losing his mother to ...
3mon
Verywell Health on MSNClostridium Perfringens: The Leading Cause of Food PoisoningClostridium perfringens (C ... your healthcare provider may prescribe antibiotics or medications to target parasites.
10d
News Medical on MSNMicrobes in your gut could determine cancer treatment outcomesResearchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment ...
Q. My son picked up an infection in the hospital recently. It sounded like the doctors were calling it “see-dift.” It gave him terrible diarrhea. Do you know what this is? A. The doctors were ...
Our Clostridium botulinum research funded by several competitive ... derived from spores are the basis of an innovative approach to the killing of antibiotic resistant bacteria. Yet, despite the ...
FORC3® is a proven solution with unparallelled results in targeting Clostridium perfringens ... "Endolysins open the doorway to the next generation of antibiotic-free production. We are delighted to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results